{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:57:46Z","timestamp":1793437066084,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"DOI":"10.1007\/s00204-026-04515-8","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:35:06Z","timestamp":1785825306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenging the specificity of chlorzoxazone and 4-nitrophenol as marker substrates for CYP2E1 activity in Supersomes\u2122"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3959-4253","authenticated-orcid":false,"given":"Anna","family":"Hellmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0817-7932","authenticated-orcid":false,"given":"Ann-Kathrin","family":"Lenich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0575-184X","authenticated-orcid":false,"given":"Stephanie","family":"Ruez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-2718","authenticated-orcid":false,"given":"J\u00f6rg","family":"Fahrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Lott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"6","key":"4515_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1021\/acs.chemrestox.5c00133","volume":"38","author":"MJ Carlsson","year":"2025","unstructured":"Carlsson MJ, Herzog N, Felske C, Ackermann G, Regier A, Wittmann S, Cereijo RF, Sturla SJ, K\u00fcpper J-H, Fahrer J (2025) The DNA repair protein MGMT protects against the genotoxicity of N-nitrosodimethylamine, but not N-nitrosodiethanolamine and N-nitrosomethylaniline, in human HepG2 liver cells with CYP2E1 expression. Chem Res Toxicol 38(6):1134\u20131146. https:\/\/doi.org\/10.1021\/acs.chemrestox.5c00133","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"4515_CR2","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1021\/tx00036a015","volume":"6","author":"V Carriere","year":"1993","unstructured":"Carriere V, Goasduff T, Ratanasavanh D, Morel F, Gautier JC, Guillouzo A, Beaune P, Berthou F (1993) Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 6(6):852\u2013857. https:\/\/doi.org\/10.1021\/tx00036a015","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"4515_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00008571-199606000-00002","volume":"6","author":"V Carri\u00e8re","year":"1996","unstructured":"Carri\u00e8re V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I (1996) Human cytochrome from genotype to phenotype. Pharmacogenetics 6(3):203\u2013211. https:\/\/doi.org\/10.1097\/00008571-199606000-00002","journal-title":"Pharmacogenetics"},{"issue":"2","key":"4515_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jchromb.2005.05.037","volume":"825","author":"MI Churchwell","year":"2005","unstructured":"Churchwell MI, Twaddle NC, Meeker LR, Doerge DR (2005) Improving LC\u2013MS sensitivity through increases in chromatographic performance: comparisons of UPLC\u2013ES\/MS\/MS to HPLC\u2013ES\/MS\/MS. J Chromatogr B Analyt Technol Biomed Life Sci 825(2):134\u2013143. https:\/\/doi.org\/10.1016\/j.jchromb.2005.05.037","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"4515_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2125.2004.02132.x","volume":"58","author":"L Ernstg\u00e5rd","year":"2004","unstructured":"Ernstg\u00e5rd L, Warholm M, Johanson G (2004) Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br J Clin Pharmacol 58(2):190\u2013200. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02132.x","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4515_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054684","volume":"24","author":"J Fahrer","year":"2023","unstructured":"Fahrer J, Christmann M (2023) DNA alkylation damage by nitrosamines and relevant DNA repair pathways. Int J Mol Sci 24(5):4684. https:\/\/doi.org\/10.3390\/ijms24054684","journal-title":"Int J Mol Sci"},{"key":"4515_CR7","unstructured":"FDA (2024) M12 Drug interaction studies"},{"issue":"68","key":"4515_CR8","doi-asserted-by":"publisher","first-page":"112199","DOI":"10.18632\/oncotarget.22937","volume":"8","author":"J Gao","year":"2017","unstructured":"Gao J, Wang G-J, Wang Z, Gao N, Li J, Zhang Y-F, Zhou J, Zhang H-X, Wen Q, Jin H, Qiao H-L (2017) High CYP2E1 activity correlates with hepatofibrogenesis induced by nitrosamines. Oncotarget 8(68):112199\u2013112210. https:\/\/doi.org\/10.18632\/oncotarget.22937","journal-title":"Oncotarget"},{"key":"4515_CR9","unstructured":"Gentest\u00ae Supersomes\u00ae (2025) https:\/\/go.dls.com\/l\/997171\/2024-05-24\/2dntk\/997171\/1716556294ZkWo1CMv\/DLS_Supersomes_Brochure_52424.pdf"},{"issue":"2","key":"4515_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1021\/tx00020a008","volume":"4","author":"FP Guengerich","year":"1991","unstructured":"Guengerich FP, Kim DH, Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4(2):168\u2013179. https:\/\/doi.org\/10.1021\/tx00020a008","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"4515_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00204-020-02939-4","volume":"95","author":"H Hammer","year":"2021","unstructured":"Hammer H, Schmidt F, Marx-Stoelting P, P\u00f6tz O, Braeuning A (2021) Cross-species analysis of hepatic cytochrome P450 and transport protein expression. Arch Toxicol 95(1):117\u2013133. https:\/\/doi.org\/10.1007\/s00204-020-02939-4","journal-title":"Arch Toxicol"},{"issue":"10","key":"4515_CR12","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1111\/bcp.14040","volume":"85","author":"N Hohmann","year":"2019","unstructured":"Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE (2019) Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. Br J Clin Pharmacol 85(10):2310\u20132320. https:\/\/doi.org\/10.1111\/bcp.14040","journal-title":"Br J Clin Pharmacol"},{"key":"4515_CR13","doi-asserted-by":"publisher","unstructured":"Koop DR, Carmen, Tierney DJ (1989) The utility of pnltrophenol hydroxylation in PWIIE1. Drug Metab Rev 20(2\u20134):541\u2013551. https:\/\/doi.org\/10.3109\/03602538909103560","DOI":"10.3109\/03602538909103560"},{"issue":"18","key":"4515_CR14","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2146\/ajhp060414","volume":"64","author":"LA Kroon","year":"2007","unstructured":"Kroon LA (2007) Drug interactions with smoking. Am J Health Syst Pharm 64(18):1917\u20131921. https:\/\/doi.org\/10.2146\/ajhp060414","journal-title":"Am J Health Syst Pharm"},{"key":"4515_CR15","doi-asserted-by":"publisher","unstructured":"K\u00fcttner J, Grzegorzewski J, Tautenhahn H-M, K\u00f6nig M (2023) A physiologically based pharmacokinetic model for CYP2E1 phenotyping via chlorzoxazone. bioRxiv, 2023.04.12.536571. https:\/\/doi.org\/10.1101\/2023.04.12.536571","DOI":"10.1101\/2023.04.12.536571"},{"key":"4515_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-025-04135-8","author":"A-K Lenich","year":"2025","unstructured":"Lenich A-K, Ruez S (2025a) Evaluating CYP enzyme induction by cigarette smoking: a new in vitro approach using primary human hepatocytes. Arch Toxicol. https:\/\/doi.org\/10.1007\/s00204-025-04135-8","journal-title":"Arch Toxicol"},{"key":"4515_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-025-04238-2","author":"A-K Lenich","year":"2025","unstructured":"Lenich A-K, Ruez S (2025b) Insights from a novel in vitro cigarette smoke induction model: comparison of 24 primary human hepatocyte donors of diverse demographics and multiple sources. Arch Toxicol. https:\/\/doi.org\/10.1007\/s00204-025-04238-2","journal-title":"Arch Toxicol"},{"issue":"4","key":"4515_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100064","volume":"53","author":"A-K Lenich","year":"2025","unstructured":"Lenich A-K, Nilles J, Scherer V, Li F, Ruez S (2025) Assessing granisetron as a specific CYP1A1 substrate in primary human hepatocytes: a comprehensive evaluation for drug development studies. Drug Metab Dispos 53(4):100064. https:\/\/doi.org\/10.1016\/j.dmd.2025.100064","journal-title":"Drug Metab Dispos"},{"key":"4515_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1239395","volume":"14","author":"X Li","year":"2023","unstructured":"Li X, Ni J, Chen L (2023) Advances in the study of acetaminophen-induced liver injury. Front Pharmacol 14:1239395. https:\/\/doi.org\/10.3389\/fphar.2023.1239395","journal-title":"Front Pharmacol"},{"key":"4515_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s0076-6879(96)72014-1","volume":"272","author":"D Lucas","year":"1996","unstructured":"Lucas D, Menez J-F, Berthou F (1996) [12] Chlorzoxazone: an in vitro and in vivo substrate probe for liver CYP2E1. Methods Enzymol 272:115\u2013123. https:\/\/doi.org\/10.1016\/s0076-6879(96)72014-1","journal-title":"Methods Enzymol"},{"issue":"3","key":"4515_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00008571-199906000-00013","volume":"9","author":"D Lucas","year":"1999","unstructured":"Lucas D, Ferrara R, Gonzalez E, Bodenez P, Albores A, Manno M, Berthou F (1999) Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 9(3):377\u2013388. https:\/\/doi.org\/10.1097\/00008571-199906000-00013","journal-title":"Pharmacogenetics"},{"issue":"4","key":"4515_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/03602532.2020.1832112","volume":"52","author":"MR McGill","year":"2020","unstructured":"McGill MR, Hinson JA (2020) The development and hepatotoxicity of acetaminophen: reviewing over a century of progress. Drug Metab Rev 52(4):472\u2013500. https:\/\/doi.org\/10.1080\/03602532.2020.1832112","journal-title":"Drug Metab Rev"},{"issue":"3","key":"4515_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00008571-199506000-00002","volume":"5","author":"S Ono","year":"1995","unstructured":"Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5(3):143\u2013150. https:\/\/doi.org\/10.1097\/00008571-199506000-00002","journal-title":"Pharmacogenetics"},{"issue":"6","key":"4515_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1021\/tx00018a012","volume":"3","author":"R Peter","year":"1990","unstructured":"Peter R, Boecker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3(6):566\u2013573. https:\/\/doi.org\/10.1021\/tx00018a012","journal-title":"Chem Res Toxicol"},{"issue":"11","key":"4515_CR25","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/0006-2952(93)90639-e","volume":"46","author":"W Tassaneeyakul","year":"1993","unstructured":"Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO (1993a) Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 46(11):1975\u20131981. https:\/\/doi.org\/10.1016\/0006-2952(93)90639-e","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4515_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0378-4347(93)80473-h","volume":"616","author":"W Tassaneeyakul","year":"1993","unstructured":"Tassaneeyakul W, Veronese ME, Birkett DJ, Miners JO (1993b) High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes. J Chromatogr B Biomed Sci Appl 616(1):73\u201378. https:\/\/doi.org\/10.1016\/0378-4347(93)80473-h","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"4515_CR27","unstructured":"WHO (2025) WHO report on the global tobacco epidemic, 2025."},{"issue":"4","key":"4515_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/00498254.2014.985760","volume":"45","author":"Y Yamamura","year":"2015","unstructured":"Yamamura Y, Koyama N, Umehara K (2015) Comprehensive kinetic analysis and influence of reaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies. Xenobiotica 45(4):353\u2013360. https:\/\/doi.org\/10.3109\/00498254.2014.985760","journal-title":"Xenobiotica"},{"issue":"1","key":"4515_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3978\/j.issn.2304-3881.2012.11.05","volume":"1","author":"Q Ye","year":"2012","unstructured":"Ye Q, Lian F, Chavez PRG, Chung J, Ling W, Qin H, Seitz HK, Wang X-D (2012) Cytochrome P450 2E1 inhibition prevents hepatic carcinogenesis induced by diethylnitrosamine in alcohol-fed rats. Hepatobiliary Surg Nutr 1(1):58\u201318. https:\/\/doi.org\/10.3978\/j.issn.2304-3881.2012.11.05","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"10","key":"4515_CR30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1021\/tx970048z","volume":"10","author":"A Zerilli","year":"1997","unstructured":"Zerilli A, Ratanasavanh D, Lucas D, Goasduff T, Dr\u00e9ano Y, Menard C, Picart D, Berthou F (1997) Both cytochromes P450 2E1 and 3A are involved in the O-hydroxylation of p-nitrophenol, a catalytic activity known to be specific for P450 2E1. Chem Res Toxicol 10(10):1205\u20131212. https:\/\/doi.org\/10.1021\/tx970048z","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"4515_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1530-0277.1998.tb04307.x","volume":"22","author":"A Zerilli","year":"1998","unstructured":"Zerilli A, Lucas D, Dreano Y, Picart D, Berthou F (1998) Effect of pyrazole and dexamethasone administration on cytochrome P450 2E1 and 3A isoforms in rat liver and kidney: lack of specificity of p\u2010nitrophenol as a substrate of P450 2E1. Alcohol Clin Exp Res 22(3):652\u2013657. https:\/\/doi.org\/10.1111\/j.1530-0277.1998.tb04307.x","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04515-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:35:09Z","timestamp":1785825309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-026-04515-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":31,"alternative-id":["4515"],"URL":"https:\/\/doi.org\/10.1007\/s00204-026-04515-8","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}